文献速递关节外科

氨甲环酸在冠状动脉疾病史患者全关节置换术中安全

Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty.
PubMed 文献 · J Bone Joint Surg Am · 2021-01-01

本研究回顾性分析单中心8年连续全髋和全膝关节置换术病例,在接受氨甲环酸的患者中识别有冠状动脉疾病或冠脉支架史者,评估术后90天内心肌梗死和静脉血栓栓塞发生率。结果显示无术后心肌梗死,静脉血栓栓塞率与对照组无显著差异,局部与静脉氨甲环酸同样安全。

要点

  • 有冠状动脉疾病史患者使用氨甲环酸后无术后心肌梗死。
  • 冠状动脉疾病史患者静脉血栓栓塞率与对照组无显著差异。
  • 局部与静脉氨甲环酸在有冠状动脉疾病或支架史患者中同样安全。

核心结论

  • 在有冠状动脉疾病和冠脉支架史患者中,局部与静脉氨甲环酸与对照组相比同样安全。

研究设计与样本

  • 单中心三级学术医疗中心回顾性分析,纳入8年间连续全髋和膝关节置换术病例。

主要发现

  • 在26,808例被识别为高危的患者中,术后无心肌梗死发生。
  • 冠状动脉疾病史患者静脉血栓栓塞率为0.29%,对照组为0.76%,差异无统计学意义(p=0.09)。
  • 冠脉支架史患者静脉血栓栓塞率为0%,对照组为0.76%,差异无统计学意义(p=0.14)。
  • 按给药途径亚组分析,冠状动脉疾病史患者静脉给药静脉血栓栓塞率0.13%,局部给药0.72%,差异无统计学意义(p=0.12)。
  • 冠脉支架史患者静脉与局部给药静脉血栓栓塞率均为0%,差异无统计学意义(p=1.0)。

关键数值与推荐

  • 推荐静脉氨甲环酸,因疗效与不良事件风险相当且更便于机构实施。
  • 证据等级为治疗性III级。

临床怎么用

  • 有冠状动脉疾病或冠脉支架史患者行全关节置换术时可安全使用氨甲环酸。
  • 静脉氨甲环酸可作为便于机构实施的优选给药方式。

局限性

  • 本研究为单中心回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) is increasingly used to minimize blood loss during total joint arthroplasty (TJA). Although TXA has been shown to be highly effective in reducing operative blood loss, many surgeons believe that it places patients with coronary artery disease (CAD) or a history of coronary stents at an increased risk for myocardial infarction. The purpose of this study was to determine if TXA is safe to use in patients with a history of CAD or coronary stents. METHODS: We performed a retrospective analysis at a single, tertiary academic medical center identifying consecutive total hip and knee arthroplasty cases over an 8-year period. From this cohort who received TXA intraoperatively, we identified patients with a history of CAD or coronary stents and determined the total myocardial infarction and venous thromboembolism (VTE) rates within a 90-day postoperative period. Chi-square analyses were used to identify differences in VTE rates between cohorts. A post hoc power analysis was also performed to determine whether our results were powered to detect a difference in VTE rates. RESULTS: In the 26,808 identified at-risk patients, there were no postoperative myocardial infarctions. No significant differences were observed for VTE rates compared with the control cohort using either topical or intravenous TXA, with regard to CAD (0.29% compared with 0.76%; p = 0.09) or coronary stents (0% compared with 0.76%; p = 0.14). Moreover, there was no significant difference observed in VTE rates when administration was subcategorized into intravenous and topical methods with regard to CAD (0.13% compared with 0.72%; p = 0.12) or coronary stents (0% compared with 0%; p = 1.0). CONCLUSIONS: In our series, topical and intravenous TXA were equally safe when used in patients with a history of CAD and coronary stents in comparison with the control cohort. With equal efficacy and risk of adverse events, we recommend intravenous TXA, which may enable easier institutional implementation. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Zak SG, Tang A, Sharan M, et al. Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. J Bone Joint Surg Am. 2021. PMID: 33983147. doi:10.2106/JBJS.20.01226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。